Colleagues,
As reported in BioTech Transfer Week ... Seattle-based biotech investment and development firm Accelerator said this week that it has formed its 10th startup, Xori, which is developing a new technology for discovering and developing monoclonal antibodies for therapeutic use.
The technology will enable Xori to identify high-affinity mAbs "within a matter of weeks, as opposed to the more traditional methods, which require many months and often fail to generate high-quality reagents," ... Investors in the company's Series A investment include Accelerator partners Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD, and WRF Capital.
Read on at:
http://www.genomeweb.com/node/917105?emc=el&m=394474&l=5&am...
ENJOY!
CC
Tags: